Memorial Sloan-Kettering
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.
Bayer Cancels Cell Therapy Licensing Deal With Atara Biotherapeutics
Bayer has notified Atara of plans to terminate its exclusive worldwide licensing deal for the mesothelin-directed cell therapies ATA3271 and ATA2271.
MSK to Launch Trial of T-Cell Receptor Therapy Targeting Common Neoantigen With Pharma Partner
Premium
The therapy, which could potentially have tissue-agnostic use, is designed to target a public neoantigen from a mutation in the oncogenic driver gene PIK3CA.
MSK Researchers Testing if Chemo-Induced Hypermutated Colon Cancers Respond to BMS'Â OpdivoÂ
Based on encouraging data in mice, investigators are assessing if temozolomide-cisplatin can make patients'Â "cold" tumors respond to checkpoint blockade.Â
In Sixth Year, Project GENIE Diversifying, Integrating Local Ancestry and Enhancing Clinical Data
Premium
Despite the registry's growth in content and utility, currently more than 80 percent of the clinical and genomic data comes from white patients, which AACR wants to change.